Â鶹ѧÉú¾«Æ·°æ

Steffen Schmitz-Valckenberg
( out of 217 reviews )

Steffen Schmitz-Valckenberg, MD

Languages spoken: German, English

Clinical Locations

Farmington Health Center

Farmington
801-213-3200

John A. Moran Eye Center

Salt Lake City
801-581-2352

Midvalley Health Center

Murray
801-581-2955

  • Steffen Schmitz-Valckenberg, MD, specializes in clinical and surgical treatment of macular and retinal diseases, including age-related macular degeneration (AMD), and is an expert in high-resolution retinal imaging.

    Dr. Schmitz-Valckenberg co-founded and directed the Grading of Digital Fundus Examination Reading Center at the University of Bonn, Germany, where he was the Department of Ophthalmology’s assistant medical director. As an expert in high-resolution retinal and fundus autofluorescence imaging, he has used various imaging techniques to map the stages of decline in AMD. Researchers worldwide use this mapping to measure outcomes during interventional clinical trials.

    At Moran, Dr. Schmitz-Valckenberg is directing an that will play a key role in the drive to take a new therapy for a prevalent form of AMD into clinical trials.

    Dr. Schmitz-Valckenberg holds a Jon M. Huntsman Presidential Chair at the University of Utah and is a prolific researcher with more than 165 publications and 120 peer-reviewed articles. His honors include being named by The Ophthalmologist to its Power List 2017: Top 50 Rising Stars.

    Get to know Dr. Schmitz-Valckenberg by watching his .

    Specialties

    Board Certification

    European Board of Ophthalmology
    Medical Association of North Rhine-Ophthalmology

    Patient Rating

    4.8 /5
    ( out of 217 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    September 29, 2024
    MORAN EYE CENTER

    Very caring

    September 26, 2024
    FARMINGTON HEALTH CENTER

    Excellent Doctor, excellent care, excellent listener with excellent problem solving skills to tailor make my care for me.

    September 26, 2024
    FARMINGTON HEALTH CENTER

    Dr V is very knowledgeable and takes great care and concern during the injections.

    September 25, 2024
    MORAN EYE CENTER

    Was very professional and friendly and I trusted her and the information she gave me.

    September 24, 2024
    MORAN EYE CENTER

    Can be hard to work with!

    September 19, 2024
    MORAN EYE CENTER

    Dr. Schmitz-Valckenberg, MD is an excellent physician. He takes time to listen to my concerns and answers all my questions. He performed my surgery, and the results were very good. I trust him with my eye care completely.

    September 14, 2024
    FARMINGTON HEALTH CENTER

    Dr Marc Steffen Schmitz-Valckenberg, MD is a very great doctor I would highly recommend him

    September 13, 2024
    FARMINGTON HEALTH CENTER

    Dr Marc Valckenberg is very professional, courteous, respectful and knowledgeable in treating my eye problem.

    September 11, 2024
    MORAN EYE CENTER

    After I had been referred to the Moran Eye Center and learned I would be seeing Dr. Schmitz-Valckenberg, I researched his background, something I normally do when not being familiar with a new specialist. That, in itself, impressed me, and although I did not spend a great deal of time with Dr. Schmitz-Valckenberg, he had thorough knowledge of my history (up to this visit), as well as all testing performed at Moran prior to seeing him. I should add that I was seen by Dr. Fairless, whom I was told worked under Dr. Schmitz-Valckenberg, prior to seeing him. Thusly, I believe I was covered excellently, while at the same time, feeling most grateful for being under the care of Dr. Schmitz-Valckenberg.

    See More Patient Comments

  • Steffen Schmitz-Valckenberg, MD, specializes in clinical and surgical treatment of macular and retinal diseases, including age-related macular degeneration (AMD), and is an expert in high-resolution retinal imaging.

    Dr. Schmitz-Valckenberg co-founded and directed the Grading of Digital Fundus Examination Reading Center at the University of Bonn, Germany, where he was the Department of Ophthalmology’s assistant medical director. As an expert in high-resolution retinal and fundus autofluorescence imaging, he has used various imaging techniques to map the stages of decline in AMD. Researchers worldwide use this mapping to measure outcomes during interventional clinical trials.

    At Moran, Dr. Schmitz-Valckenberg is directing an that will play a key role in the drive to take a new therapy for a prevalent form of AMD into clinical trials.

    Dr. Schmitz-Valckenberg holds a Jon M. Huntsman Presidential Chair at the University of Utah and is a prolific researcher with more than 165 publications and 120 peer-reviewed articles. His honors include being named by The Ophthalmologist to its Power List 2017: Top 50 Rising Stars.

    Get to know Dr. Schmitz-Valckenberg by watching his .

    Board Certification and Academic Information

    Academic Departments Ophthalmology & Visual Sciences -Primary
    Board Certification
    European Board of Ophthalmology
    Medical Association of North Rhine-Ophthalmology

    Education history

    Professional Medical Medicine - Ruprecht-Karls-University Heidelberg M.D.

    Selected Publications

    Journal Article

    1. de Vente C, Valmaggia P, Hoyng CB, Holz FG, Islam MM, Klaver CCW, Boon CJF, Schmitz-Valckenberg S, Tufail A, Samannshausen M, Snchez CI, MACUSTAR Consortium (2024). Generalizable Deep Learning for the Detection of Incomplete and Complete Retinal Pigment Epithelium and Outer Retinal Atrophy: A MACUSTAR Report. Transl Vis Sci Technol, 13(9), 11. ()
    2. Knzel SH, Broadbent E, Mller PT, Lindner M, Goerdt L, Czauderna J, Schmitz-Valckenberg S, Holz FG, Pfau M, Fleckenstein M (2024). Association of Lesion Location and Functional Parameters with Vision-Related Quality of Life in Geographic Atrophy Secondary to Age-related Macular Degeneration. Ophthalmol Retina, 8(8), 794-803. ()
    3. Samannshausen M, Dngelci S, Vaisband M, von der Emde L, Sloan KR, Hasenauer J, Holz FG, Schmitz-Valckenberg S, Ach T (2024). Spatially Resolved Association of Structural Biomarkers on Retinal Function in Non-Exudative Age-Related Macular Degeneration Over 4 Years. Invest Ophthalmol Vis Sci, 65(4), 45. ()
    4. Zouache MA, Richards BT, Pappas CM, Anstadt RA, Liu J, Corsetti T, Matthews S, Seager NA, Schmitz-Valckenberg S, Fleckenstein M, Hubbard WC, Thomas J, Hageman JL, Williams BL, Hageman GS (2024). Levels of complement factor H-related 4 protein do not influence susceptibility to age-related macular degeneration or its course of progression. Nat Commun, 15(1), 443. ()
    5. Guymer R, Bailey C, Chaikitmongkol V, Chakravarthy U, Chaudhary V, Finger RP, Gallego-Pinazo R, Chuan AKH, Ishida S, Lvestam-Adrian M, Parravano M, Luna Pinto JD, Schmitz-Valckenberg S, Sheth V, Souied EH, Chi GC, Gilberg F, Glittenberg C, Scheidl S, Bengus M (2023). Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice. Ophthalmol Sci, 4(3), 100442. ()
    6. von der Emde L, Mallwitz M, Vaisband M, Hasenauer J, Samannshausen M, Terheyden JH, MACUSTAR Consortium, Sloan KR, Schmitz-Valckenberg S, Finger RP, Holz FG, Ach T (2023). Retest variability and patient reliability indices of quantitative fundus autofluorescence in age-related macular degeneration: a MACUSTAR study report. Sci Rep, 13(1), 17417. ()
    7. Weber C, Stasik I, Herrmann P, Schmitz-Valckenberg S, Holz FG, Liegl R (2023). Early Vitrectomy with Silicone Oil Tamponade in the Management of Postoperative Endophthalmitis. J Clin Med, 12(15). ()
    8. Schmitz-Valckenberg S, Samannshausen M, Braun M, Steffen V, Gao SS, Honigberg L, Ferrara D, Pfau M, Holz FG (2023). Inter-Reader Agreement and Longitudinal Progression of Incomplete/Complete Retinal Pigment Epithelium and Outer Retinal Atrophy in AMD. Ophthalmol Retina. ()
    9. Spaide T, Jiang J, Patil J, Anegondi N, Steffen V, Kawczynski MG, Newton EM, Rabe C, Gao SS, Lee AY, Holz FG, Sadda S, Schmitz-Valckenberg S, Ferrara D (2023). Geographic Atrophy Segmentation Using Multimodal Deep Learning. Transl Vis Sci Technol, 12(7), 10. ()
    10. Wu Z, Schmitz-Valckenberg S, Blodi BA, Holz FG, Jaffe GJ, Liakopoulos S, Sadda SR, Bonse M, Brown T, Choong J, Clifton B, Corradetti G, Corvi F, Dieu AC, Dooling V, Pak JW, Samannshausen M, Skalak C, Thiele S, Guymer RH (2023). Reticular Pseudodrusen: Interreader Agreement of Evaluation on OCT Imaging in Age-Related Macular Degeneration. Ophthalmol Sci, 3(4), 100325. ()
    11. Dhooge PPA, Mller PT, Meland N, Stingl K, Boon CJF, Lotery AJ, Parodi MB, Herrmann P, Klein W, Fsadni MG, Wheeler-Schilling TH, Holz FG, Hoyng CB, Schmitz-Valckenberg S, Soraprazan Consortium (2023). Repeatability of Quantitative Autofluorescence Imaging in a Multicenter Study Involving Patients With Recessive Stargardt Disease 1. Transl Vis Sci Technol, 12(2), 1. ()
    12. Samannshausen M, Behning C, Weinz J, Goerdt L, Terheyden JH, Chang P, Schmid M, Poor SH, Zakaria N, Finger RP, Holz FG, Pfau M, Schmitz-Valckenberg S, Thiele S, MACUSTAR consortium members (2022). Characteristics and Spatial Distribution of Structural Features in Age-Related Macular Degeneration: A MACUSTAR Study Report. Ophthalmol Retina. ()
    13. Garzone D, Terheyden JH, Morelle O, Wintergerst MWM, Samannshausen M, Schmitz-Valckenberg S, Pfau M, Thiele S, Poor S, Leal S, Holz FG, Finger RP, MACUSTAR Consortium (2022). Comparability of automated drusen volume measurements in age-related macular degeneration: a MACUSTAR study report. Sci Rep, 12(1), 21911. ()
    14. Pfau M, Schmitz-Valckenberg S, Ribeiro R, Safaei R, McKeown A, Fleckenstein M, Holz FG (2022). Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy. Sci Rep, 12(1), 17870. ()
    15. Dhooge PPA, Mller PT, Boon CJF, Lotery AJ, Herrmann P, Battaglia Parodi M, Klein W, Fsadni MG, Wheeler-Schilling TH, Jungmann O, Mller H, Holz FG, Schmitz-Valckenberg S, Peters TM, Stingl K, Hoyng CB, Soraprazan Consortium (2022). The STArgardt Remofuscin Treatment Trial (STARTT): design and baseline characteristics of enrolled Stargardt patients. Open Res Eur, 1, 96. ()
    16. Faatz H, Feltgen N, Gutfleisch M, Heimes-Bussmann B, Krohne TU, Liakopoulos S, Liegl R, Lommatzsch A, Mussinghoff P, Rehak M, Schmitz-Valckenberg S, Spital G, Stanzel B, Ziemssen F, Hgele B, Junkes C, Porstner M, Vgeler J, Gmeiner B, Pauleikhoff D (2022). [Prospective noninterventional BLUE SKY study evaluating the efficacy of brolucizumab in treatment-naïve and previously treated patients with neovascular AMD]. Ophthalmologie. ()
    17. Samannshausen M, Behning C, Isselmann B, Schmid M, Finger RP, Holz FG, Schmitz-Valckenberg S, Pfau M, MACUSTAR Consortium, Thiele S (2022). Relative ellipsoid zone reflectivity and its association with disease severity in age-related macular degeneration: a MACUSTAR study report. Sci Rep, 12(1), 14933. ()
    18. Bindewald-Wittich A, Dolar-Szczasny J, Kuenzel SH, von der Emde L, Pfau M, Rejdak R, Schmitz-Valckenberg S, Ach T, Dreyhaupt J, Holz FG (2022). Blue-light fundus autofluorescence imaging of pigment epithelial detachments. Eye (Lond). ()
    19. Samannshausen M, Thiele S, Behning C, Pfau M, Schmid M, Leal S, Luhmann UFO, Finger RP, Holz FG, Schmitz-Valckenberg S, MACUSTAR Consortium (2022). Intersession Repeatability of Structural Biomarkers in Early and Intermediate Age-Related Macular Degeneration: A MACUSTAR Study Report. Transl Vis Sci Technol, 11(3), 27. ()
    20. Schmitz-Valckenberg S, Fleckenstein M, Zouache MA, Pfau M, Pappas C, Hageman JL, Agrn E, Malley C, Keenan TDL, Chew EY, Hageman GS (2022). Progression of Age-Related Macular Degeneration Among Individuals Homozygous for Risk Alleles on Chromosome 1 (CFH-CFHR5) or Chromosome 10 (ARMS2/HTRA1) or Both. JAMA Ophthalmol, 140(3), 252-260. ()
    21. Holz FG, Schmitz-Valckenberg S, Wolf A, Agostini H, Lorenz K, Pielen A, Feltgen N, Guthoff R, Quiering C, Clemens A, Jaeger K (2022). A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration-the FALCON study. Graefes Arch Clin Exp Ophthalmol. ()
    22. Rieck S, Kilgus S, Meyer JH, Huang H, Zhao L, Matthey M, Wang X, Schmitz-Valckenberg S, Fleischmann BK, Wenzel D (2021). Inhibition of Vascular Growth by Modulation of the Anandamide/Fatty Acid Amide Hydrolase Axis. Arterioscler Thromb Vasc Biol, 41(12), 2974-2989. ()
    23. Knzel SH, Lindner M, Sassen J, Mller PT, Goerdt L, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M, Pfau M (2022). Association of Reading Performance in Geographic Atrophy Secondary to Age-Related Macular Degeneration With Visual Function and Structural Biomarkers. JAMA Ophthalmol, 139(11), 1191-1199. ()
    24. Pfau M, van Dijk EHC, van Rijssen TJ, Schmitz-Valckenberg S, Holz FG, Fleckenstein M, Boon CJF (2021). Estimation of current and post-treatment retinal function in chronic central serous chorioretinopathy using artificial intelligence. Sci Rep, 11(1), 20446. ()
    25. Behning C, Fleckenstein M, Pfau M, Adrion C, Goerdt L, Lindner M, Schmitz-Valckenberg S, Holz FG, Schmid M (2021). Modeling of atrophy size trajectories: variable transformation, prediction and age-of-onset estimation. BMC Med Res Methodol, 21(1), 170. ()
    26. von der Emde L, Pfau M, Holz FG, Fleckenstein M, Kortuem K, Keane PA, Rubin DL, Schmitz-Valckenberg S (2021). AI-based structure-function correlation in age-related macular degeneration. Eye (Lond), 35(8), 2110-2118. ()
    27. Schmitz-Valckenberg S, Braun MD, Thiele S, Ferrara D, Honigberg L, Gao SS, Chen H, Steffen V, Holz FG, Samannshausen M (2021). Conversion from Intermediate Age-Related Macular Degeneration to Geographic Atrophy in a Proxima B Subcohort Using a Multimodal Approach. Ophthalmologica, 244(6), 523-534. ()
    28. Pfau M, Sahu S, Rupnow RA, Romond K, Millet D, Holz FG, Schmitz-Valckenberg S, Fleckenstein M, Lim JI, de Sisternes L, Leng T, Rubin DL, Hallak JA (2021). Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration. Transl Vis Sci Technol, 10(7), 30. ()
    29. Fleckenstein M, Keenan TDL, Guymer RH, Chakravarthy U, Schmitz-Valckenberg S, Klaver CC, Wong WT, Chew EY (2021). Age-related macular degeneration. Nat Rev Dis Primers, 7(1), 31. ()
    30. Holz FG, Oleksy P, Ricci F, Kaiser PK, Kiefer J, Schmitz-Valckenberg S, COLUMBUS-AMD Study Group (2021). Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology, 129, 54-63. ()
    31. Pfau M, Jolly JK, Wu Z, Denniss J, Lad EM, Guymer RH, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2020). Fundus-controlled perimetry (microperimetry): Application as outcome measure in clinical trials. Prog Retin Eye Res, 82, 100907. ()
    32. Wu Z, Pfau M, Blodi BA, Holz FG, Jaffe GJ, Liakopoulos S, Sadda SR, Staurenghi G, Bjelopera E, Brown T, Chang P, Choong J, Corradetti G, Corvi F, Domalpally A, Hurtenbach C, Nittala MG, Olson A, Pak JW, Pappe J, Samannshausen M, Skalak C, Thiele S, Guymer RH, Schmitz-Valckenberg S (2021). OCT Signs of Early Atrophy in Age-Related Macular Degeneration: Interreader Agreement: Classification of Atrophy Meetings Report 6. Ophthalmol Retina, 6, 4-14. ()
    33. Samannshausen M, Zhou J, Pfau M, Thiele S, Steinberg J, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2020). Longitudinal Analysis of Retinal Thickness and Retinal Function in Eyes with Large Drusen Secondary to Intermediate Age-Related Macular Degeneration. Ophthalmol Retina, 5(3), 241-250. ()
    34. Schmitz-Valckenberg S, Pfau M, Fleckenstein M, Staurenghi G, Sparrow JR, Bindewald-Wittich A, Spaide RF, Wolf S, Sadda SR, Holz FG (2020). Fundus autofluorescence imaging. Prog Retin Eye Res, 81, 100893. ()
    35. Barkana Y, Pondorfer SG, Schmitz-Valckenberg S, Russ H, Finger RP (2021). Improved sensitivity of microperimetric outcomes for clinical studies in age-related macular degeneration. Sci Rep, 11(1), 4764. ()
    36. Mller PL, Pfau M, Schmitz-Valckenberg S, Fleckenstein M, Holz FG (2020). Optical Coherence Tomography-Angiography in Geographic Atrophy. Ophthalmologica, 244(1), 42-50. ()
    37. Huss MB, Schmitz-Valckenberg S, Finger RP, Lffler KU, Fleckenstein M, Holz FG, Pfau M (2020). The Willingness of Patients to Participate in an Eye Donation Registry for Research. Ophthalmologica, 244(3), 179-186. ()
    38. Jaffe GJ, Chakravarthy U, Freund KB, Guymer RH, Holz FG, Liakopoulos S, Mons JM, Rosenfeld PJ, Sadda SR, Sarraf D, Schmitz-Valckenberg S, Spaide RF, Staurenghi G, Tufail A, Curcio CA (2020). Imaging Features Associated with Progression to Geographic Atrophy in Age-Related Macular Degeneration: Classification of Atrophy Meeting Report 5. Ophthalmol Retina, 5, 855-867. ()
    39. Pfau M, von der Emde L, de Sisternes L, Hallak JA, Leng T, Schmitz-Valckenberg S, Holz FG, Fleckenstein M, Rubin DL (2020). Progression of Photoreceptor Degeneration in Geographic Atrophy Secondary to Age-related Macular Degeneration. JAMA Ophthalmol, 138(10), 1026-1034. ()
    40. Pfau M, Walther G, von der Emde L, Berens P, Faes L, Fleckenstein M, Heeren TFC, Kortm K, Knzel SH, Mller PL, Maloca PM, Waldstein SM, Wintergerst MWM, Schmitz-Valckenberg S, Finger RP, Holz FG (2020). [Artificial intelligence in ophthalmology : Guidelines for physicians for the critical evaluation of studies]. Ophthalmologe, 117(10), 973-988. ()
    41. Pfau M, von der Emde L, Dysli C, Mller PT, Thiele S, Lindner M, Schmid M, Rubin DL, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2020). Determinants of Cone and Rod Functions in Geographic Atrophy: AI-Based Structure-Function Correlation. Am J Ophthalmol, 217, 162-173. ()
    42. Sassmannshausen M, Pfau M, Thiele S, Fimmers R, Steinberg JS, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2020). Longitudinal Analysis of Structural and Functional Changes in Presence of Reticular Pseudodrusen Associated With Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci, 61(10), 19. ()
    43. Terheyden JH, Holz FG, Schmitz-Valckenberg S, Lning A, Schmid M, Rubin GS, Dunbar H, Tufail A, Crabb DP, Binns A, Snchez CI, Hoyng C, Margaron P, Zakaria N, Durbin M, Luhmann U, Zamiri P, Cunha-Vaz J, Martinho C, Leal S, Finger RP, MACUSTAR consortium (2020). Clinical study protocol for a low-interventional study in intermediate age-related macular degeneration developing novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention-MACUSTAR. Trials, 21(1), 659. ()
    44. Wachtlin J, Spital G, Schmitz-Valckenberg S, Liakopoulos S, Vgeler J, Mller B, Ziemssen F, Ocean Study Group (2020). Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany. J Ophthalmol, 2020, 8024258. ()
    45. Berger M, Schmid M, Welchowski T, Schmitz-Valckenberg S, Beyersmann J (2018). Subdistribution hazard models for competing risks in discrete time. Biostatistics, 21(3), 449-466. ()
    46. Meyer JH, Marx J, Strack C, Holz FG, Schmitz-Valckenberg S (2020). Imaging of Therapeutic Effects of Anti-Vascular Endothelial Growth Factor Inhibitors by Optical Coherence Tomography Angiography in a Rat Model. Transl Vis Sci Technol, 9(7), 29. ()
    47. Holekamp N, Wykoff CC, Schmitz-Valckenberg S, Mons J, Souied EH, Lin H, Rabena MD, Cantrell RA, Henry EC, Tang F, Swaminathan B, Martin J, Ferrara D, Staurenghi G (2019). Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials. Ophthalmology, 127(6), 769-783. ()
    48. Raber FP, Reinking K, Schmitz-Valckenberg S, Althaus K, Kaut O, Witry M, Lang GE (2020). [Successful Systemic Lysis Therapy in Acute Retinal Arterial Occlusions]. Klin Monbl Augenheilkd, 237(6), 772-779. ()
    49. Knzel SH, Mller PT, Lindner M, Goerdt L, Nadal J, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M, Pfau M (2020). Determinants of Quality of Life in Geographic Atrophy Secondary to Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci, 61(5), 63. ()
    50. Pielen A, Feltgen N, Hattenbach LO, Hoerauf H, Bertelmann T, Quiering C, Vgeler J, Priglinger S, Lang GE, Schmitz-Valckenberg S, Wolf A, Rehak M (2019). Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: Post-hoc Analysis from the COMRADE Trials. Curr Eye Res, 45(5), 604-614. ()
    51. Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, Waheed NK, Chakravarthy U, Rosenfeld PJ, Holz FG, Souied EH, Cohen SY, Querques G, Ohno-Matsui K, Boyer D, Gaudric A, Blodi B, Baumal CR, Li X, Coscas GJ, Brucker A, Singerman L, Luthert P, Schmitz-Valckenberg S, Schmidt-Erfurth U, Grossniklaus HE, Wilson DJ, Guymer R, Yannuzzi LA, Chew EY, Csaky K, Mons JM, Pauleikhoff D, Tadayoni R, Fujimoto J (2019). Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology, 127(5), 616-636. ()
    52. Schmitz-Valckenberg S, Brasse K, Hoerauf H (2020). [Vitreous floaters]. Ophthalmologe, 117(5), 485-496. ()
    53. Wintergerst MWM, Gorgi Zadeh S, Wiens V, Thiele S, Schmitz-Valckenberg S, Holz FG, Finger RP, Schultz T (2020). Replication and Refinement of an Algorithm for Automated Drusen Segmentation on Optical Coherence Tomography. Sci Rep, 10(1), 7395. ()
    54. Thiele S, Nadal J, Pfau M, Samannshausen M, Fleckenstein M, Holz FG, Schmid M, Schmitz-Valckenberg S (2020). Prognostic value of intermediate age-related macular degeneration phenotypes for geographic atrophy progression. Br J Ophthalmol. ()
    55. Schmitz-Valckenberg S, Khlewein L, Waldstein SM, Spital G, Ziemssen F, Liakopoulos S (2020). Second Opinion in Retinal Imaging. Ophthalmologe, 117(4), 326-330.
    56. Gale RP, Pearce I, Eter N, Ghanchi F, Holz FG, Schmitz-Valckenberg S, Balaskas K, Burton BJL, Downes SM, Eleftheriadis H, George S, Gilmour D, Hamilton R, Lotery AJ, Patel N, Prakash P, Santiago C, Thomas S, Varma D, Walters G, Williams M, Wolf A, Zakri RH, Igwe F, Ayan F (2019). Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. Br J Ophthalmol, 104(4), 493-499. ()
    57. Guymer RH, Rosenfeld PJ, Curcio CA, Holz FG, Staurenghi G, Freund KB, Schmitz-Valckenberg S, Sparrow J, Spaide RF, Tufail A, Chakravarthy U, Jaffe GJ, Csaky K, Sarraf D, Mons JM, Tadayoni R, Grunwald J, Bottoni F, Liakopoulos S, Pauleikhoff D, Pagliarini S, Chew EY, Viola F, Fleckenstein M, Blodi BA, Lim TH, Chong V, Lutty J, Bird AC, Sadda SR (2019). Incomplete Retinal Pigment Epithelial and Outer Retinal Atrophy in Age-Related Macular Degeneration: Classification of Atrophy Meeting Report 4. Ophthalmology, 127(3), 394-409. ()
    58. Pfau M, Mller PT, Knzel SH, von der Emde L, Lindner M, Thiele S, Dysli C, Nadal J, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (2019). Type 1 Choroidal Neovascularization Is Associated with Reduced Localized Progression of Atrophy in Age-Related Macular Degeneration. Ophthalmol Retina, 4(3), 238-248. ()
    59. Liakopoulos S, Spital G, Brinkmann CK, Schick T, Ziemssen F, Voegeler J, Koch M, Kirchhof B, Holz FG, Pauleikhoff D, Schmitz-Valckenberg S (2020). ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD). Br J Ophthalmol. ()
    60. Thiele S, Nadal J, Pfau M, Samannshausen M, von der Emde L, Fleckenstein M, Holz FG, Schmid M, Schmitz-Valckenberg S, Molecular Diagnostic of Age-related Macular Degeneration Study Group (2019). Prognostic Value of Retinal Layers in Comparison with Other Risk Factors for Conversion of Intermediate Age-related Macular Degeneration. Ophthalmol Retina, 4(1), 31-40. ()
    61. von der Emde L, Thiele S, Pfau M, Nadal J, Meyer J, Mller PT, Schmid M, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2019). Assessment of Exudative Activity of Choroidal Neovascularization in Age-Related Macular Degeneration by OCT Angiography. Ophthalmologica, 243(2), 120-128. ()
    62. Pfau M, Mller PL, von der Emde L, Lindner M, Mller PT, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2018). MESOPIC AND DARK-ADAPTED TWO-COLOR FUNDUS-CONTROLLED PERIMETRY IN GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina, 40(1), 169-180. ()
    63. Terheyden JH, Finger RP, Schmitz-Valckenberg S, Agostini H, Dahlke C, Kuehlewein L, Lang GE, Pauleikhoff D, Wolf A, Boettger MK, Luhmann UFO, Asmus F, Holz FG, MACUSTAR-Konsortium (2019). [Development and validation of novel clinical endpoints in intermediate age-related macular degeneration in MACUSTAR]. Ophthalmologe, 116(12), 1186-1193. ()
    64. Callizo J, Ziemssen F, Bertelmann T, Feltgen N, Vgeler J, Koch M, Eter N, Liakopoulos S, Schmitz-Valckenberg S, Spital G (2019). Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study. Clin Ophthalmol, 13, 2167-2179. ()
    65. Pfau M, von der Emde L, Dysli C, Thiele S, Mller PT, Lindner M, Nadal J, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (2019). Light Sensitivity Within Areas of Geographic Atrophy Secondary to Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci, 60(12), 3992-4001. ()
    66. Fleckenstein M, Thiele S, Pfau M, Schmitz-Valckenberg S, Holz FG (2019). [Dry Age-Related Macular Degeneration - Epidemiology and Classification]. Klin Monbl Augenheilkd, 236(9), 1068-1075. ()
    67. Pfau M, Lindner M, Goerdt L, Thiele S, Nadal J, Schmid M, Schmitz-Valckenberg S, Sadda SR, Holz FG, Fleckenstein M, Fundus Autofluorescence in Age-Related Macular Degeneration Study Group (2018). PROGNOSTIC VALUE OF SHAPE-DESCRIPTIVE FACTORS FOR THE PROGRESSION OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina, 39(8), 1527-1540. ()
    68. von der Emde L, Pfau M, Dysli C, Thiele S, Mller PT, Lindner M, Schmid M, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2019). Artificial intelligence for morphology-based function prediction in neovascular age-related macular degeneration. Sci Rep, 9(1), 11132. ()
    69. Meyer JH, Larsen PP, Strack C, Harmening WM, Krohne TU, Holz FG, Schmitz-Valckenberg S (2019). Optical coherence tomography angiography (OCT-A) in an animal model of laser-induced choroidal neovascularization. Exp Eye Res, 184, 162-171. ()
    70. Gattoussi S, Buitendijk GHS, Peto T, Leung I, Schmitz-Valckenberg S, Oishi A, Wolf S, Dek G, Delcourt C, Klaver CCW, Korobelnik JF, European Eye Epidemiology E3 consortium (2018). The European Eye Epidemiology spectral-domain optical coherence tomography classification of macular diseases for epidemiological studies. Acta Ophthalmol, 97(4), 364-371. ()
    71. Grassmann F, Harsch S, Brandl C, Kiel C, Nrnberg P, Toliat MR, Fleckenstein M, Pfau M, Schmitz-Valckenberg S, Holz FG, Chew EY, Swaroop A, Ratnapriya R, Klein ML, Mulyukov Z, Zamiri P, Weber BHF (2019). Assessment of Novel Genome-Wide Significant Gene Loci and Lesion Growth in Geographic Atrophy Secondary to Age-Related Macular Degeneration. JAMA Ophthalmol. ()
    72. Lindner M, Pfau M, Czauderna J, Goerdt L, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (2018). Determinants of Reading Performance in Eyes with Foveal-Sparing Geographic Atrophy. Ophthalmol Retina, 3(3), 201-210. ()
    73. Brasse K, Schmitz-Valckenberg S, Jnemann A, Roider J, Hoerauf H (2018). [YAG laser vitreolysis for treatment of symptomatic vitreous opacities]. Ophthalmologe, 116(1), 73-84. ()
    74. Finger RP, Schmitz-Valckenberg S, Schmid M, Rubin GS, Dunbar H, Tufail A, Crabb DP, Binns A, Snchez CI, Margaron P, Normand G, Durbin MK, Luhmann UFO, Zamiri P, Cunha-Vaz J, Asmus F, Holz FG, onbehalfoftheMACUSTARconsortium (2018). MACUSTAR: Development and Clinical Validation of Functional, Structural, and Patient-Reported Endpoints in Intermediate Age-Related Macular Degeneration. Ophthalmologica, 241(2), 61-72. ()
    75. Fang PP, Domdei N, Herrmann P, Schmitz-Valckenberg S, Holz FG, Harmening WM, Krohne TU (2017). MINIMAL OPTICAL COHERENCE TOMOGRAPHY B-SCAN DENSITY FOR RELIABLE DETECTION OF INTRARETINAL AND SUBRETINAL FLUID IN MACULAR DISEASES. Retina, 39(1), 150-156. ()
    76. Ziemssen F, Wachtlin J, Kuehlewein L, Gamulescu MA, Bertelmann T, Feucht N, Voegeler J, Koch M, Liakopoulos S, Schmitz-Valckenberg S, Spital G, OCEAN study group (2018). Intravitreal Ranibizumab Therapy for Diabetic Macular Edema in Routine Practice: Two-Year Real-Life Data from a Non-interventional, Multicenter Study in Germany. Diabetes Ther, 9(6), 2271-2289. ()
    77. Pfau M, Lindner M, Gliem M, Steinberg JS, Thiele S, Finger RP, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2018). Mesopic and dark-adapted two-color fundus-controlled perimetry in patients with cuticular, reticular, and soft drusen. Eye (Lond), 32(12), 1819-1830. ()
    78. Feltgen N, Hattenbach LO, Bertelmann T, Callizo J, Rehak M, Wolf A, Berk H, Eter N, Lang GE, Pielen A, Schmitz-Valckenberg S, Quiering C, Rose U, Hoerauf H, COMRADE Study Group (2018). Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study. Acta Ophthalmol, 96(8), e933-e941. ()
    79. Brinkmann CK, Chang P, Schick T, Heimes B, Vgeler J, Haegele B, Kirchhof B, Holz FG, Pauleikhoff D, Ziemssen F, Liakopoulos S, Spital G, Schmitz-Valckenberg S (2018). Initial diagnosis and indication for anti-vascular endothelial growth factor therapy in retinal diseases. Ophthalmologe.
    80. Mller PL, Pfau M, Mauschitz MM, Mller PT, Birtel J, Chang P, Gliem M, Schmitz-Valckenberg S, Fleckenstein M, Holz FG, Herrmann P (2018). Comparison of Green Versus Blue Fundus Autofluorescence in ABCA4-Related Retinopathy. Transl Vis Sci Technol, 7(5), 13. ()
    81. Paul C, Krug P, Muller HH, Wachtlin J, Mennel S, Muller S, Schmitz-Valckenberg S, Bertelmann T, Schumann RG (2018). Comparison of the horizontal diameter to a modeled area of traction in eyes with vitreomacular traction: is the diameter close enough to the truth? Graefes Arch Clin Exp Ophthalmol, 256(10), 1817-1822. ()
    82. Pfau M, Lindner M, Steinberg JS, Thiele S, Brinkmann CK, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2018). Visual field indices and patterns of visual field deficits in mesopic and dark-adapted two-colour fundus-controlled perimetry in macular diseases. Br J Ophthalmol, 102(8), 1054-1059. ()
    83. Paul C, Heun C, Mller HH, Hoerauf H, Feltgen N, Wachtlin J, Kaymak H, Mennel S, Koss MJ, Fauser S, Maier MM, Schumann RG, Mueller S, Chang P, Schmitz-Valckenberg S, Kazerounian S, Szurman P, Lommatzsch A, Bertelmann T (2018). Calculating the individual probability of successful ocriplasmin treatment in eyes with VMT syndrome: a multivariable prediction model from the EXPORT study. Br J Ophthalmol, 102(8), 1092-1097. ()
    84. Welker SG, Pfau M, Heinemann M, Schmitz-Valckenberg S, Holz FG, Finger RP (2018). Retest Reliability of Mesopic and Dark-Adapted Microperimetry in Patients With Intermediate Age-Related Macular Degeneration and Age-Matched Controls. Invest Ophthalmol Vis Sci, 59(4), AMD152-AMD159. ()
    85. Mller PL, Pfau M, Mller PT, Nadal J, Schmid M, Lindner M, de Sisternes L, Sthr H, Weber BHF, Neuhaus C, Herrmann P, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (2018). Choroidal Flow Signal in Late-Onset Stargardt Disease and Age-Related Macular Degeneration: An OCT-Angiography Study. Invest Ophthalmol Vis Sci, 59(4), AMD122-AMD131. ()
    86. Lindner M, Kosanetzky S, Pfau M, Nadal J, Gordt LA, Schmitz-Valckenberg S, Schmid M, Holz FG, Fleckenstein M (2018). Local Progression Kinetics of Geographic Atrophy in Age-Related Macular Degeneration Are Associated With Atrophy Border Morphology. Invest Ophthalmol Vis Sci, 59(4), AMD12-AMD18. ()
    87. Thiele S, Pfau M, Larsen PP, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2018). Multimodal Imaging Patterns for Development of Central Atrophy Secondary to Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci, 59(4), AMD1-AMD11. ()
    88. Sassmannshausen M, Steinberg JS, Fimmers R, Pfau M, Thiele S, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2018). Structure-Function Analysis in Patients With Intermediate Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci, 59(3), 1599-1608. ()
    89. Hattenbach LO, Feltgen N, Bertelmann T, Schmitz-Valckenberg S, Berk H, Eter N, Lang GE, Rehak M, Taylor SR, Wolf A, Weiss C, Paulus EM, Pielen A, Hoerauf H (2018). Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmol, 96(1), e10-e18. ()
    90. von der Emde L, Pfau M, Thiele S, Mller PT, Hassenrik R, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2018). Mesopic and Dark-Adapted Two-Color Fundus-Controlled Perimetry in Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Transl Vis Sci Technol, 8(1), 7. ()

    Review

    1. Chang P, von der Emde L, Pfau M, Knzel S, Fleckenstein M, Schmitz-Valckenberg S, Holz FG (2024). [Use of artificial intelligence in geographic atrophy in age-related macular degeneration]. [Review]. Ophthalmologie, 121(8), 616-622. ()
    2. Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U (2024). Age-Related Macular Degeneration: A Review. [Review]. JAMA, 331(2), 147-157. ()
    3. Pfau M, Knzel SH, Pfau K, Schmitz-Valckenberg S, Fleckenstein M, Holz FG (2023). Multimodal imaging and deep learning in geographic atrophy secondary to age-related macular degeneration. [Review]. Acta Ophthalmol, 101(8), 881-890. ()
    4. Kaiser PK, Schmitz-Valckenberg MS, Holz FG (2022). ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR BIOSIMILARS IN OPHTHALMOLOGY. [Review]. Retina, 42(12), 2243-2250. ()
    5. Terheyden JH, Schmitz-Valckenberg S, Crabb DP, Dunbar H, Luhmann UFO, Behning C, Schmid M, Silva R, Cunha-Vaz J, Tufail A, Weissgerber G, Leal S, Holz FG, Finger RP, onbehalfoftheMACUSTARConsortium (2020). Use of Composite End Points in Early and Intermediate Age-Related Macular Degeneration Clinical Trials: State-of-the-Art and Future Directions. [Review]. Ophthalmologica, 244(5), 387-395. ()
    6. Mller PL, Wolf S, Dolz-Marco R, Tafreshi A, Schmitz-Valckenberg S, Holz FG, Bille JF (2019). Ophthalmic Diagnostic Imaging: Retina. [Review]. ()

    Conference Proceedings

    1. Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, Blodi BA, Bottoni F, Chakravarthy U, Chew EY, Csaky K, Danis RP, Fleckenstein M, Freund KB, Grunwald J, Hoyng CB, Jaffe GJ, Liakopoulos S, Mons JM, Pauleikhoff D, Rosenfeld PJ, Sarraf D, Spaide RF, Tadayoni R, Tufail A, Wolf S, Staurenghi G (2018). Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology, United States, 125(4), 537-548. ()

    Editorial

    1. Holz FG, Schmitz-Valckenberg S (2024). [Artificial intelligence (AI) in age-related macular degeneration]. Ophthalmologie, 121(8), 607-608. ()

    Letter

    1. Pfau M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (2022). Re: Trivizki et al. Local Geographic Atrophy Growth Rates Not Influenced by Close Proximity to Non-Exudative Type 1 Macular Neovascularization. [Letter to the editor]. Invest Ophthalmol Vis Sci, 63(5), 10. ()

    Other

    1. Garzone D, Terheyden JH, Morelle O, Wintergerst MWM, Samannshausen M, Schmitz-Valckenberg S, Pfau M, Thiele S, Poor S, Leal S, Holz FG, Finger RP, MACUSTAR Consortium (2023). Author Correction: Comparability of automated drusen volume measurements in age-related macular degeneration: a MACUSTAR study report. Sci Rep (13(1), p. 3795). England. ()